Opinion|Videos|July 16, 2024
Perspectives on Shared Decision-Making in the Treatment of CLL
Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Examine the importance of patient preferences and patient involvement in the shared decision-making process to individualize treatment and improve outcomes.
- How do you assess and incorporate patient preferences into treatment selection?
- What insights/implications do data recently presented at EHA 2023 offer?
Advertisement
Related to this article
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.
Advertisement
Advertisement
Trending on OncLive
1
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
2
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
3
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
4
Updated NCCN Guidelines Recommend Rusfertide Across Polycythemia Vera
5